Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

DR. LAL PATHLABS LTD.

NSE : LALPATHLABBSE : 539524ISIN CODE : INE600L01024Industry : Hospital & Healthcare ServicesHouse : Arvind Lal

BSE1726.4533.6 (+1.98 %)

PREV CLOSE ( ) 1692.85

OPEN PRICE ( ) 1677.30

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 17911

TODAY'S LOW / HIGH ( )1671.90 1737.90

52 WK LOW / HIGH ( )1272 1803.6

NSE1725.1032.3 (+1.91 %)

PREV CLOSE( ) 1692.80

OPEN PRICE ( ) 1692.00

BID PRICE (QTY) 1725.10 (1437)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 334674

TODAY'S LOW / HIGH( ) 1672.50 1738.00

52 WK LOW / HIGH ( )1272.6 1803

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 14-02 1995

Management Info

Arvind Lal - Chairman - Managing Director

Registered Office

Address Block E,Sector 18,Rohini,
New Delhi,
Delhi-110085

Phone 011-30258600 / 49885050

Email lalpathlabs@lalpathlabs.com / cs@lalpathlabs.com

Website www.lalpathlabs.com

Registrars Details

MUFG Intime India Pvt Ltd.

Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi

Listing : BSE, NSE

NEWS

02Jul Dr. Lal PathLabs informs about newspap
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

13Jun Dr. Lal Pathlabs incorporates wholly o
Dr. Lal Pathlabs has incorporated Wholly Owned Subsidiary (WOS) in the n..

02May Dr. Lal PathLabs informs about update
In continuation to its earlier intimation dated April 30, 2026 with resp..

24Apr Dr. Lal PathLabs informs about analyst
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

06Jan Dr. Lal PathLabs sets new standard in
Dr. Lal PathLabs has launched its new-age Diagnostic Experience Centre -..

Financials

Rs. in Millions

	QTR Mar 26	ANNUAL 26
Net Profit	1411	5082
Gross Profit	1699	6602
Operating Profit	2185	8664
Net Sales	6752	26476

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr Agarwals Eye Hosp (BSE) 4999.40 (1.93%)	M.Cap ( in Cr)2416.12
Kovai Medical Center (BSE) 5998.00 (0.28%)	M.Cap ( in Cr)6563.17
Yatharth Hospital (BSE) 845.55 (1.88%)	M.Cap ( in Cr)8147.24
Dr. Agarwal's Health (BSE) 497.20 (2.85%)	M.Cap ( in Cr)15762.54
Healthcare Global (BSE) 679.10 (1.68%)	M.Cap ( in Cr)10139.11

Shareholding Pattern

	PROMOTERS	53.21%
	MUTUAL FUNDS/UTI	18.62%
	NON-INSTITUTION	8.35%
	FI/BANKS/INSURANCE	2.33%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
NJ ELSS Tax Saver S...	3.99
Bajaj Finserv Healt...	2.82
PGIM India Healthca...	2.36
Nippon India Pharma...	2.31
Quantum Ethical Fun...	2.15
DSP Nifty Smallcap2...	2.09
NJ Flexi Cap Fund-Reg(G)	2.03

Risk Disclosures on Derivatives

Smart Quotes

DR. LAL PATHLABS LTD.